



Audited Financial Results for the year ended 31st March, 2005

Rs. in lakhs

PARTICULARS	FIGURES FOR THE NINE MONTHS (APRIL-DEC, 2004)	FIGURES FOR THE LAST QUARTER (JAN-MAR, 2005)	FIGURES FOR THE CORRESPONDING QUARTER OF THE PREVIOUS YEAR	AUDITED FIGURES FOR THE CURRENT YEAR (2004-2005)	AUDITED FIGURES FOR THE PREVIOUS YEAR (2003-2004)
01. Net Sales / Income from Operations (including Sales Tax)	12299	3702	3624	16001	13550
02. Other Income	1118	1020	652	2138	1832
TOTAL	13417	4722	4276	18139	15382
03. Total Expenditure	10320	3563	3369	13883	11705
a) Increase / Decrease in Stock-in-Trade	-215	300	-155	85	79
b) Consumption of Raw Materials	5587	1233	1761	6820	5868
c) Staff Cost	1215	559	382	1774	1340
d) Other Expenditure (any item exceeding 10% of the total expenditure to be shown separately)	3733	1471	1381	5204	4418
04. Interest	1014	239	180	1253	1278
05. Depreciation	414	170	120	584	477
06. Profit before tax	1669	750	605	2419	1920
07. Provisions / write offs	-	2344	495	2344	520
08. Provision for Taxation (including deferred tax)	-	-81		-81	529
09. Net Profit	1669	-1513	110	156	871
10. Paid-up Equity Share Capital	2338	2616	2338	2616	2338
11. Reserves excluding revaluation reserves	-		-	6669	3430
12. Basic and diluted EPS for the period (not annualized, on profit after tax)	7.14		0.47	0.60	3.73
13. Aggregate of non-promoter shareholding: Number of Shares Percentage of Shareholding				9,218,880 35.24	6,389,837 27.33

- 1) The above audited financial results for the three months ended on 31st March, 2005 were considered and taken on record by the Board of Directors at a meeting held at Hyderabad, on Thursday, the 30th June, 2005.
- 2) An amount of Rs. 2344 lakhs, representing doubtful debts and advances have been written off in the books of accounts for the year ended on 31st March, 2005.

Dated at Hyderabad, this, the 30th June, 2005.

for and on behalf of the Board of Directors,
NATCO Pharma Limited,

V.C. Nannapaneni
Chairman & Managing Director

Status of investor complaints as at 31-Mar-2005 :

Pending as on 1 st January, 2005	Nil
Received during the quarter	107
Resolved during the quarter	107
Pending as on 31 st March, 2005	Nil

NATCO Pharma Limited
Regd. Office : NATCO House,
Road # 2, Banjara Hills,
Hyderabad : 500 033.



Report of segment wise Revenue, Results and Capital Employed, under Clause 41 of the Listing Agreement, for the quarter ended on 31st March, 2005

Rs. lakhs

Particulars	Three months ended on 31 st March, 2005	Corresponding three months in the previous year	Year to date figures for the current year 2004-2005	Previous Accounting Year (2003-2004)
1. Segment Revenue (net sales / income, including Sales Tax)				
a) Bulk Chemicals	2487	2018	10265	8127
b) Formulations	1180	1661	5928	5915
c) Job Work	189	211	995	878
d) Others	896	440	1204	954
Total	4753	4330	18393	15874
Less : Inter-segment Revenue	30	54	253	491
Net Sales / Income from Operations	4722	4276	18139	15382
2. Segment Results : Profit (+) / Loss (-) before tax and interest				
a) Bulk Chemicals	952	946	4693	3509
b) Formulations	-312	-198	-725	-283
c) Job Work	92	106	635	566
d) Others	897	234	1205	494
Total	1629	1088	5808	4286
Less : a) Interest	239	180	1254	1278
b) Other un-allocable expenditure net of un-allocable income	2984	798	4479	1608
Total Profit before Tax	-1594	110	75	1400
3. Capital Employed (Segment Assets – Segment Liabilities)				
a) Bulk Chemicals	6367	3903	6367	3903
b) Formulations	3739	3001	3739	3001
c) Job Work		-		-
d) Others		-		-
Total	10106	6904	10106	6904

The above report of segment-wise revenue, results and capital employed for the three months ended on 31st March, 2005 was considered and taken on record by the Board of Directors at a meeting held at Hyderabad, on Thursday, the 30th June, 2005.

Dated at Hyderabad, this, the 30th day of June, 2005.

for and on behalf of the Board of Directors,
NATCO Pharma Limited,

V.C. Nannapaneni
Chairman & Managing Director

NATCO Pharma Limited
Regd. Office : NATCO House,
Road # 2, Banjara Hills PO,

Hyderabad : 500 033